Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,296 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07810933RecruitingPhase 1/Phase 2
Study of a new ALK inhibitor for advanced cancer
This trial tests a new pill, SY-12321, for people with advanced cancer that has a specific change called ALK. The study aims to see if the drug can shrink tumors or slow their growth, and it may be an option if you've already tried other ALK-targeting treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06336707RecruitingPhase 1
HS-20089 combination for advanced solid tumors
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06514313RecruitingPhase 2
Study of a drug combo for children with returning soft tissue sarcoma
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Guangzhou, GuangdongAges 2–21 - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06015048RecruitingPhase 1/Phase 2
SHR-A1811 plus other therapies for advanced HER2+ tumors
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
Hefei, AnhuiAges 18–75 - NCT07787208RecruitingPhase 1
Experimental drug for advanced solid tumors
This trial tests an investigational drug called ONO-7429 for people with advanced or recurrent solid tumors that have not responded to standard treatments. The goal is to see if the drug can help control the cancer.
Kashiwa, ChibaAges 18 years+ - NCT06506838RecruitingPhase 4
Anlotinib, chemo, and radiation before sarcoma surgery
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT05068583Recruiting
Testing liquid blood samples in children with certain cancers
This trial studies “liquid biopsies,” which are blood tests, to help learn about specific cancers in children. It may help doctors monitor cancer and guide treatment using less invasive tests.
Los Angeles, CaliforniaAges 6 months+ - NCT07753226RecruitingPhase 1
Study of SI-B036 for advanced breast cancer and other solid tumors
This study tests a new drug called SI-B036 for people with advanced breast cancer or other solid tumors that have spread. The goal is to see if the drug is safe and to find the best dose.
Beijing, Beijing MunicipalityAges 18–75 - NCT07744763RecruitingPhase 1/Phase 2
Study of SYS6041 for advanced solid tumors
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07744074Recruiting
Carbon-ion radiation for large chest tumors
This trial tests a new type of radiation using carbon ions to treat large tumors in the chest that have come back or not responded to prior treatments. It aims to see if this therapy is safe and effective for people who have few options.
Hangzhou, ZhejiangAges 18 years+ - NCT06515626RecruitingEarly Phase 1
Modified t cells for multiple cancers
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
Zhengzhou, HenanAges 18–75 - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT07728942RecruitingPhase 1
SLR-108 PET imaging study for metastatic solid tumors
This trial uses a special imaging agent called SLR-108 to take detailed PET scans of your cancer. It aims to see if this scan can help doctors better understand metastatic solid tumors that have grown after previous treatment.
Newport Beach, CaliforniaAges 18 years+ - NCT07727434Recruiting
Stress and Anxiety in People Having Biopsy for Bone or Soft Tissue Cancer
This study looks at how stress and anxiety levels change in people who are about to have a biopsy for a possible bone or soft tissue tumor. The goal is to better understand the emotional impact of waiting for results and starting treatment.
IstanbulAges 18 years+ - NCT07719920RecruitingPhase 1
Study of HW221043 for advanced solid tumors
This trial is testing a new oral drug called HW221043 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06637007RecruitingPhase 2
Chidamide plus AK112 for advanced sarcoma after first treatment
This trial tests two new drugs (chidamide and AK112) together for people with advanced bone or soft tissue sarcoma that has not responded to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–75 - NCT07701941RecruitingPhase 1/Phase 2
Combination treatment for advanced breast cancer
This trial tests two targeted drugs together for people with advanced breast cancer that is hormone receptor positive and has low levels of a protein called HER2. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07700160RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT07670312RecruitingPhase 1/Phase 2
Testing XYA02 for advanced solid tumors
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
Sydney, New South WalesAges 18 years+ - NCT07667842RecruitingPhase 1
Study of D3L-002 for advanced solid tumors
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
Macquarie ParkAges 18 years+ - NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,296 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.